ABSTRACT
Glycoscience research has been significantly impeded by the complex compositions of the glycans present in biological molecules and the lack of convenient tools suitable for studying the glycosylation process and its function. Polysaccharides and glycoconjugates are not encoded directly by genes; instead, their biosynthesis relies on the differential expression of carbohydrate enzymes, resulting in heterogeneous mixtures of glycoforms, each with a distinct physiological activity. Access to well-defined structures is required for functional study, and this has been provided by chemical and enzymatic synthesis and by the engineering of glycosylation pathways. This review covers general methods for preparing glycans commonly found in mammalian systems and applying them to the synthesis of therapeutically significant glycoconjugates (glycosaminoglycans, glycoproteins, glycolipids, glycosylphosphatidylinositol-anchored proteins) and the development of carbohydrate-based vaccines.
Subject(s)
Glycoconjugates/chemical synthesis , Glycoproteins/chemical synthesis , Glycosaminoglycans/chemical synthesis , Haemophilus Infections/prevention & control , Haemophilus Vaccines/administration & dosage , Polysaccharides/chemical synthesis , Amino Acid Sequence , Carbohydrate Conformation , Carbohydrate Sequence , Glycoconjugates/immunology , Glycolipids/chemical synthesis , Glycolipids/immunology , Glycoproteins/immunology , Glycosaminoglycans/immunology , Glycosylation , Glycosylphosphatidylinositols/chemical synthesis , Glycosylphosphatidylinositols/immunology , Haemophilus Infections/immunology , Haemophilus Infections/microbiology , Haemophilus Vaccines/chemical synthesis , Haemophilus influenzae type b/drug effects , Haemophilus influenzae type b/growth & development , Haemophilus influenzae type b/pathogenicity , Humans , Polysaccharides/immunologyABSTRACT
Mycobacterium tuberculosis (Mtb) enters the host in aerosol droplets deposited in lung alveoli, where the bacteria first encounter lung-resident alveolar macrophages. We studied the earliest mycobacterium-macrophage interactions in the optically transparent zebrafish. First-responding resident macrophages phagocytosed and eradicated infecting mycobacteria, suggesting that to establish a successful infection, mycobacteria must escape out of the initially infected resident macrophage into growth-permissive monocytes. We defined a critical role for mycobacterial membrane phenolic glycolipid (PGL) in engineering this transition. PGL activated the STING cytosolic sensing pathway in resident macrophages, inducing the production of the chemokine CCL2, which in turn recruited circulating CCR2+ monocytes toward infection. Transient fusion of infected macrophages with CCR2+ monocytes enabled bacterial transfer and subsequent dissemination, and interrupting this transfer so as to prolong mycobacterial sojourn in resident macrophages promoted clearing of infection. Human alveolar macrophages produced CCL2 in a PGL-dependent fashion following infection, arguing for the potential of PGL-blocking interventions or PGL-targeting vaccine strategies in the prevention of tuberculosis. VIDEO ABSTRACT.
Subject(s)
Glycolipids/immunology , Macrophages/microbiology , Macrophages/physiology , Mycobacterium tuberculosis/immunology , Animals , Chemokine CCL2/metabolism , Chemotaxis/immunology , Cytokines/metabolism , Disease Models, Animal , Gene Knockout Techniques , Humans , Inflammation Mediators/metabolism , Macrophages, Alveolar/microbiology , Macrophages, Alveolar/physiology , Membrane Proteins/metabolism , Monocytes/immunology , Monocytes/metabolism , Monocytes/microbiology , Mutation , Mycobacterium tuberculosis/genetics , Organ Specificity/immunology , Tuberculosis/immunology , Tuberculosis/metabolism , Tuberculosis/microbiology , ZebrafishABSTRACT
Acinetobacter baumannii has emerged as an important nosocomial pathogen, particularly for patients in intensive care units and with invasive indwelling devices. The most recent clinical isolates are resistant to several classes of clinically important antibiotics, greatly restricting the ability to effectively treat critically ill patients. The bacterial envelope is an important driver of A. baumannii disease, both at the level of battling against antibiotic therapy and at the level of protecting from host innate immune function. This review provides a comprehensive overview of key features of the envelope that interface with both the host and antimicrobial therapies. Carbohydrate structures that contribute to protecting from the host are detailed, and mutations that alter these structures, resulting in increased antimicrobial resistance, are explored. In addition, protein complexes involved in both intermicrobial and host-microbe interactions are described. Finally we discuss regulatory mechanisms that control the nature of the cell envelope and its impact on host innate immune function.
Subject(s)
Acinetobacter baumannii , Cell Wall/immunology , Drug Resistance, Multiple, Bacterial/genetics , Glycolipids , Virulence/genetics , Acinetobacter baumannii/cytology , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/genetics , Acinetobacter baumannii/immunology , Adhesins, Bacterial/genetics , Adhesins, Bacterial/metabolism , Anti-Bacterial Agents/pharmacology , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/metabolism , Bacterial Proteins/metabolism , Biofilms , Cell Wall/microbiology , Cross Infection , Fimbriae Proteins/genetics , Fimbriae Proteins/metabolism , Fimbriae, Bacterial/genetics , Fimbriae, Bacterial/metabolism , Genes, Bacterial , Glycolipids/immunology , Glycolipids/metabolism , Host Microbial Interactions , Humans , Immunity, Innate , Ion Channels/genetics , Ion Channels/metabolism , Lipopolysaccharides/immunology , Lipopolysaccharides/metabolism , Microbial Interactions , Polysaccharides, Bacterial , Porins/genetics , Porins/metabolism , Type II Secretion Systems/genetics , Type II Secretion Systems/metabolism , Type VI Secretion Systems/genetics , Type VI Secretion Systems/metabolism , beta-Glucans/immunology , beta-Glucans/metabolismABSTRACT
DAT2 is a member of the diacyl trehalose family (DAT) of antigenic glycolipids located in the mycomembrane of Mycobacterium tuberculosis (Mtb). Recently it was shown that the molecular structure of DAT2 had been incorrectly assigned, but the correct structure remained elusive. Herein, the correct molecular structure of DAT2 and its methyl-branched acyl substituent mycolipanolic acid is determined. For this, four different stereoisomers of mycolipanolic acid were prepared in a stereoselective and unified manner, and incorporated into DAT2. A rigorous comparison of the four isomers to the DAT isolated from Mtb H37Rv by NMR, HPLC, GC, and mass spectrometry allowed a structural revision of mycolipanolic acid and DAT2. Activation of the macrophage inducible Ca2+-dependent lectin receptor (Mincle) with all four stereoisomers shows that the natural stereochemistry of mycolipanolic acid / DAT2 provides the strongest activation, which indicates its high antigenicity and potential application in serodiagnostics and vaccine adjuvants.
Subject(s)
Glycolipids , Mycobacterium tuberculosis , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/chemistry , Glycolipids/chemistry , Glycolipids/chemical synthesis , Glycolipids/immunology , Stereoisomerism , Molecular StructureABSTRACT
Natural killer T cells (NKT cells) recognize glycolipid antigens presented by CD1d. These cells express an evolutionarily conserved, invariant T cell antigen receptor (TCR), but the forces that drive TCR conservation have remained uncertain. Here we show that NKT cells recognized diacylglycerol-containing glycolipids from Streptococcus pneumoniae, the leading cause of community-acquired pneumonia, and group B Streptococcus, which causes neonatal sepsis and meningitis. Furthermore, CD1d-dependent responses by NKT cells were required for activation and host protection. The glycolipid response was dependent on vaccenic acid, which is present in low concentrations in mammalian cells. Our results show how microbial lipids position the sugar for recognition by the invariant TCR and, most notably, extend the range of microbes recognized by this conserved TCR to several clinically important bacteria.
Subject(s)
Glycolipids/immunology , Gram-Positive Bacteria/immunology , Natural Killer T-Cells/immunology , Animals , Antigens, CD1d/chemistry , Antigens, CD1d/physiology , Cell Line , Glycolipids/chemistry , Humans , Interferon-gamma/biosynthesis , Mice , Mice, Inbred C57BL , Receptors, Antigen, T-Cell/metabolismABSTRACT
Tuberculosis (TB) is a chronic infectious disease mainly caused by Mycobacterium tuberculosis (M. tuberculosis). The structures of polysaccharides and glycolipids at M. tuberculosis cell wall vary among different strains, which affect the physiology and pathogenesis of mycobacteria by activating or inhibiting innate and acquired immunity. Among them, some components such as lipomannan (LM) and lipoarabinomannan (LAM) activate innate immunity by recognizing some kinds of pattern recognition receptors (PRRs) like Toll-like receptors, while other components like mannose-capped lipoarabinomannan (ManLAM) could prevent innate immune responses by inhibiting the secretion of pro-inflammatory cytokines and maturation of phagosomes. In addition, many glycolipids can activate natural killer T (NKT) cells and CD1-restricted T cells to produce interferon-γ (IFN-γ). Furthermore, humoral immunity against cell wall components, such as antibodies against LAM, plays a role in immunity against M. tuberculosis infection. Cell wall polysaccharides and glycolipids of M. tuberculosis have potential applications as antigens and adjuvants for novel TB subunit vaccines.
Subject(s)
Glycolipids , Immunity, Innate , Mycobacterium tuberculosis , Tuberculosis , Mycobacterium tuberculosis/immunology , Humans , Glycolipids/immunology , Tuberculosis/immunology , Immunity, Innate/immunology , Animals , Cell Wall/immunology , Antigens, Bacterial/immunology , Tuberculosis Vaccines/immunology , Lipopolysaccharides/immunology , Immunity, Humoral/immunology , Natural Killer T-Cells/immunology , Polysaccharides, Bacterial/immunology , Adaptive Immunity/immunology , Interferon-gamma/immunology , Interferon-gamma/metabolismABSTRACT
Glycosylceramides in mammalian species are thought to be present in the form of ß-anomers. This conclusion was reinforced by the identification of only one glucosylceramide and one galactosylceramide synthase, both ß-transferases, in mammalian genomes. Thus, the possibility that small amounts of α-anomers could be produced by an alternative enzymatic pathway, by an unfaithful enzyme, or spontaneously in unusual cellular compartments has not been examined in detail. We approached the question by taking advantage of the exquisite specificity of T and B lymphocytes and combined it with the specificity of catabolic enzymes of the sphingolipid pathway. Here, we demonstrate that mammalian immune cells produce constitutively very small quantities of α-glycosylceramides, which are the major endogenous ligands of natural killer T cells. Catabolic enzymes of the ceramide and glycolipid pathway tightly control the amount of these α-glycosylceramides. The exploitation of this pathway to manipulate the immune response will create new therapeutic opportunities.
Subject(s)
B-Lymphocytes/enzymology , Glucosylceramides/biosynthesis , Natural Killer T-Cells/immunology , T-Lymphocytes/enzymology , Animals , Antigens, CD1d , Cell Line , Glucosylceramides/immunology , Glycolipids/immunology , Humans , Lymphocyte Activation/immunology , Mice , Protein BindingABSTRACT
Intradermal vaccination with Mycobacterium bovis bacillus Calmette-Guérin (BCG) protects infants from disseminated tuberculosis, and i.v. BCG protects nonhuman primates (NHP) against pulmonary and extrapulmonary tuberculosis. In humans and NHP, protection is thought to be mediated by T cells, which typically recognize bacterial peptide Ags bound to MHC proteins. However, during vertebrate evolution, T cells acquired the capacity to recognize lipid Ags bound to CD1a, CD1b, and CD1c proteins expressed on APCs. It is unknown whether BCG induces T cell immunity to mycobacterial lipids and whether CD1-restricted T cells are resident in the lung. In this study, we developed and validated Macaca mulatta (Mamu) CD1b and CD1c tetramers to probe ex vivo phenotypes and functions of T cells specific for glucose monomycolate (GMM), an immunodominant mycobacterial lipid Ag. We discovered that CD1b and CD1c present GMM to T cells in both humans and NHP. We show that GMM-specific T cells are expanded in rhesus macaque blood 4 wk after i.v. BCG, which has been shown to protect NHP with near-sterilizing efficacy upon M. tuberculosis challenge. After vaccination, these T cells are detected at high frequency within bronchoalveolar fluid and express CD69 and CD103, markers associated with resident memory T cells. Thus, our data expand the repertoire of T cells known to be induced by whole cell mycobacterial vaccines, such as BCG, and show that lipid Ag-specific T cells are resident in the lungs, where they may contribute to protective immunity.
Subject(s)
Antigens, Bacterial/immunology , BCG Vaccine/administration & dosage , Glycolipids/immunology , T-Lymphocytes/immunology , Tuberculosis/prevention & control , Adolescent , Animals , Antigens, Bacterial/metabolism , Antigens, CD1/metabolism , Cell Line , Child , Cohort Studies , Disease Models, Animal , Female , Glycoproteins/metabolism , Healthy Volunteers , Humans , Injections, Intravenous , Lung/cytology , Lung/immunology , Lung/microbiology , Macaca mulatta , Male , Mycobacterium bovis/immunology , Mycobacterium tuberculosis/immunology , Primary Cell Culture , T-Lymphocytes/metabolism , Tuberculosis/blood , Tuberculosis/immunology , Tuberculosis/microbiologyABSTRACT
Whereas proteolytic cleavage is crucial for peptide presentation by classical major histocompatibility complex (MHC) proteins to T cells, glycolipids presented by CD1 molecules are typically presented in an unmodified form. However, the mycobacterial lipid antigen mannosyl-ß1-phosphomycoketide (MPM) may be processed through hydrolysis in antigen presenting cells, forming mannose and phosphomycoketide (PM). To further test the hypothesis that some lipid antigens are processed, and to generate antigens that lead to defined epitopes for future tuberculosis vaccines or diagnostic tests, we aimed to create hydrolysis-resistant MPM variants that retain their antigenicity. Here, we designed and tested three different, versatile synthetic strategies to chemically stabilize MPM analogs. Crystallographic studies of CD1c complexes with these three new MPM analogs showed anchoring of the lipid tail and phosphate group that is highly comparable to nature-identical MPM, with considerable conformational flexibility for the mannose head group. MPM-3, a difluoromethylene-modified version of MPM that is resistant to hydrolysis, showed altered recognition by cells, but not by CD1c proteins, supporting the cellular antigen processing hypothesis. Furthermore, the synthetic analogs elicited T cell responses that were cross-reactive with nature-identical MPM, fulfilling important requirements for future clinical use.
Subject(s)
Antigens, Bacterial/chemistry , Antigens, CD1/chemistry , Glycolipids/chemistry , Glycoproteins/chemistry , Mycobacterium tuberculosis/chemistry , Phospholipids/chemistry , T-Lymphocytes/chemistry , Antigens, Bacterial/immunology , Antigens, CD1/immunology , Cell Line, Transformed , Crystallography, X-Ray , Glycolipids/immunology , Glycoproteins/immunology , Humans , Mycobacterium tuberculosis/immunology , Phospholipids/immunology , T-Lymphocytes/immunologyABSTRACT
Invariant natural killer T cells (iNKT cells) are involved in the host defense against microbial infection. Although it is known that iNKT cells recognize glycolipids presented by CD1d, how and where they encounter antigen in vivo remains unclear. Here we used multiphoton microscopy to visualize the dynamics and activation of iNKT cells in lymph nodes. After antigen administration, iNKT cells became confined in a CD1d-dependent manner in close proximity to subcapsular sinus CD169(+) macrophages. These macrophages retained, internalized and presented lipid antigen and were required for iNKT cell activation, cytokine production and population expansion. Thus, CD169(+) macrophages can act as true antigen-presenting cells controlling early iNKT cell activation and favoring the fast initiation of immune responses.
Subject(s)
Antigen Presentation/immunology , Glycolipids/immunology , Lymph Nodes/immunology , Lymphocyte Activation/immunology , Macrophages/immunology , Natural Killer T-Cells/immunology , Animals , Antigens/immunology , Cell Separation , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Lymph Nodes/cytology , Macrophages/metabolism , Membrane Glycoproteins/immunology , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microscopy, Confocal , Microscopy, Fluorescence, Multiphoton , Receptors, Immunologic/immunology , Receptors, Immunologic/metabolism , Sialic Acid Binding Ig-like Lectin 1ABSTRACT
Guillain-Barré syndrome (GBS) and Fisher syndrome (FS) are acute autoimmune neuropathies, often preceded by an infection. Antiglycolipid antibody titres are frequently elevated in sera from the acute-phase patients. Particularly, IgG anti-GQ1b antibodies are positive in as high as 90% of FS cases and thus useful for diagnosis. The development of animal models of antiglycolipid antibody-mediated neuropathies proved that some of these antibodies are directly involved in the pathogenetic mechanisms by binding to the regions where the respective target glycolipid is specifically localised. Discovery of the presence of the antibodies that specifically recognise a new conformational epitope formed by two different gangliosides (ganglioside complex) in the acute-phase sera of some patients with GBS suggested the carbohydrate-carbohydrate interaction between glycolipids. This finding indicated the need for further research in basic glycobiological science. Antiglycolipid antibodies, in particular antigangliosides antibodies, are mostly detected in acute motor axonal neuropathy type of GBS and in FS, and less frequently in the acute inflammatory demyelinating polyneuropathy (AIDP) type of GBS or in central nervous system (CNS) diseases. In the future, the search for the putative antibodies in AIDP and those that might be present in CNS diseases should continue. In addition, more efficient standardisation of antiglycolipid antibody detection methods and use as biomarkers in daily clinical practice in neurology is needed.
Subject(s)
Antibodies/metabolism , Glycolipids/immunology , Miller Fisher Syndrome/diagnosis , Miller Fisher Syndrome/metabolism , Biomarkers/metabolism , Humans , Miller Fisher Syndrome/etiologyABSTRACT
MHC class I-like CD1 molecules have evolved to present lipid-based antigens to T cells. Differences in the antigen-binding clefts of the CD1 family members determine the conformation and size of the lipids that are presented, although the factors that shape CD1 diversity remain unclear. In mice, two homologous genes, CD1D1 and CD1D2, encode the CD1d protein, which is essential to the development and function of natural killer T (NKT) cells. However, it remains unclear whether both CD1d isoforms are equivalent in their antigen presentation capacity and functions. Here, we report that CD1d2 molecules are expressed in the thymus of some mouse strains, where they select functional type I NKT cells. Intriguingly, the T cell antigen receptor repertoire and phenotype of CD1d2-selected type I NKT cells in CD1D1-/- mice differed from CD1d1-selected type I NKT cells. The structures of CD1d2 in complex with endogenous lipids and a truncated acyl-chain analog of α-galactosylceramide revealed that its A'-pocket was restricted in size compared with CD1d1. Accordingly, CD1d2 molecules could not present glycolipid antigens with long acyl chains efficiently, favoring the presentation of short acyl chain antigens. These results indicate that the two CD1d molecules present different sets of self-antigen(s) in the mouse thymus, thereby impacting the development of invariant NKT cells.
Subject(s)
Antigen Presentation/immunology , Antigens, CD1d/physiology , Cell Differentiation , Glycolipids/immunology , Killer Cells, Natural/immunology , Thymus Gland/immunology , Animals , Cells, Cultured , Crystallography, X-Ray , Killer Cells, Natural/cytology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Protein Conformation , Protein Isoforms , Thymus Gland/cytologyABSTRACT
Receptor-interacting protein kinase 3 (RIPK3) is a key regulator of programmed cell death and inflammation during viral infection or sterile tissue injury. Whether and how bacterial infection also activates RIPK3-dependent immune responses remains poorly understood. Here we show that bacterial lipids (lipid IVa or lipid A) form a complex with high mobility group box 1 (HMGB1), released by activated immune cells or damaged tissue during bacterial infection, and that this complex triggers RIPK3- and TIR domain-containing adapter-inducing IFN-ß (TRIF)-dependent immune responses. We found that these responses lead to macrophage death, interleukin (IL)-1α release, and IL-1ß maturation. In an air-pouch inflammatory infiltration model, genetic deletion of Ripk3, Trif, or IL-1 receptor (Il-1R), or monoclonal antibody-mediated HMGB1 neutralization uniformly attenuated inflammatory responses induced by Gram-negative bacteria that release lipid IVa and lipid A. These findings uncover a previously unrecognized mechanism by which host factors and bacterial components work in concert to orchestrate immune responses.
Subject(s)
Apoptosis , HMGB1 Protein/metabolism , Lipid A/metabolism , Necroptosis , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , Adaptor Proteins, Vesicular Transport/metabolism , Animals , Antibodies, Monoclonal/immunology , Glycolipids/immunology , Glycolipids/metabolism , Gram-Negative Bacteria/metabolism , HMGB1 Protein/immunology , Humans , Inflammation/metabolism , Inflammation/pathology , Interleukin-1alpha/metabolism , Interleukin-1beta/metabolism , Lipid A/analogs & derivatives , Lipid A/immunology , Macrophages/cytology , Macrophages/metabolism , Mice , Mice, Knockout , Protein Binding , Signal Transduction , Toll-Like Receptor 4/metabolismABSTRACT
BACKGROUND: Often, patients with primary immunodeficiency diseases (PID), which are marked by the absence or loss of functional antibodies, require lifelong treatment with immunoglobulin (IG) replacement therapy administered either intravenously (intravenous immunoglobulin [IVIG]) or subcutaneously (subcutaneous immunoglobulin [SCIG]). In patients with PID, the 20% SCIG product, Ig20Gly, was shown to be efficacious and well tolerated in 2 phase 2/3 trials conducted in North America and Europe. This analysis evaluated patient satisfaction with Ig20Gly therapy and treatment preferences. METHODS: This prespecified post hoc analysis showed combined data from 2 Ig20Gly pivotal trials. Treatment satisfaction was assessed in the pre-Ig20Gly period and after ≥11 months of Ig20Gly treatment using the Life Quality Index (LQI; both studies) and the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9; North American study only). Treatment preference was assessed using a survey at the end of the European study. Median within-patient differences in LQI and TSQM-9 scores between the pre-Ig20Gly period and the end of the Ig20Gly treatment period were assessed using the Wilcoxon signed-rank test. RESULTS: A total of 113 patients (n = 68 [North American]; n = 45 [Europe]) with PID were included in the analysis. In the combined LQI analysis (n = 110), significant improvements were observed in the treatment interference (median ∆: + 2.8; P = 0.006) and therapy setting (median ∆: + 5.6; P < 0.0001) domains, and in the item-level scores for convenience (median ∆: + 1.0; P < 0.0001) and interference with work/school (median ∆: + 1.0; P = 0.0001) categories. In the subgroup analyses, significant improvements in the treatment interference and therapy setting domains and the convenience and interference with work/school items were observed for those who had previously received treatment outside the home, those who had previously received IVIG, and those in the North American study. Significant improvements were observed in the TSQM-9 treatment convenience domain (median ∆: + 11.1; P < 0.0001) and selected item-level scores in the North American study. In the European study, most (88.9%) patients preferred to continue Ig20Gly versus other IG treatments. CONCLUSIONS: After ≥11 months of taking Ig20Gly, patients reported high levels of treatment satisfaction, convenience, and preference for Ig20Gly, with consistent results across studies and use of multiple patient-reported outcome measures.
Subject(s)
Glycolipids/immunology , Immunoglobulins, Intravenous/immunology , Primary Immunodeficiency Diseases/immunology , Primary Immunodeficiency Diseases/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Female , Humans , Male , Middle Aged , Quality of Life , Young AdultABSTRACT
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one-third of the world's population and causes 1.5 million deaths each year. The cell envelopes of mycobacteria comprise a wealth of unique glycolipids, including trehalose-6,6'-dimycolate (TDM), lipoarabinomannan (LAM), lipomannan (LM), and phosphatidylinositol (PI) mannosides (PIMs). These lipids are important modulators of the host immune responses during infection and in some cases have been used as adjuvants [e.g., complete Freund's adjuvant (CFA)]. Despite this abundant basic knowledge, the identities of the host immune receptors for mycobacterial lipids have long been elusive. Here we review and summarize our current state of knowledge regarding innate immune receptors for mycobacteria, focusing particularly on immunoreceptor tyrosine-based activation motif (ITAM)-coupled C-type lectin receptors (CLRs), which have been shown to recognize mycobacteria-derived glycolipids.
Subject(s)
Glycolipids/immunology , Immunity, Innate , Immunologic Factors/immunology , Lectins, C-Type/metabolism , Mycobacterium tuberculosis/immunology , Tuberculosis/immunology , Adjuvants, Immunologic , Animals , Host-Pathogen Interactions , Humans , Lectins, C-Type/immunologyABSTRACT
Natural killer T (NKT) cells respond to a variety of CD1d-restricted antigens (Ags), although the basis for Ag discrimination by the NKT cell receptor (TCR) is unclear. Here we have described NKT TCR fine specificity against several closely related Ags, termed altered glycolipid ligands (AGLs), which differentially stimulate NKT cells. The structures of five ternary complexes all revealed similar docking. Acyl chain modifications did not affect the interaction, but reduced NKT cell proliferation, indicating an affect on Ag processing or presentation. Conversely, truncation of the phytosphingosine chain caused an induced fit mode of TCR binding that affected TCR affinity. Modifications in the glycosyl head group had a direct impact on the TCR interaction and associated cellular response, with ligand potency reflecting the t(1/2) life of the interaction. Accordingly, we have provided a molecular basis for understanding how modifications in AGLs can result in striking alterations in the cellular response of NKT cells.
Subject(s)
Antigens, CD1d/immunology , Epitopes , Natural Killer T-Cells/immunology , Animals , Carbohydrate Sequence , Cell Line , Cell Proliferation , Glycolipids/immunology , Mice , Mice, Inbred C57BL , Models, Molecular , Molecular Sequence Data , Natural Killer T-Cells/cytology , Receptors, Natural Killer Cell/immunologyABSTRACT
The evolutionary survival of Mycobacterium tuberculosis, the cause of human tuberculosis, depends on its ability to invade the host, replicate, and transmit infection. At its initial peripheral infection site in the distal lung airways, M. tuberculosis infects macrophages, which transport it to deeper tissues. How mycobacteria survive in these broadly microbicidal cells is an important question. Here we show in mice and zebrafish that M. tuberculosis, and its close pathogenic relative Mycobacterium marinum, preferentially recruit and infect permissive macrophages while evading microbicidal ones. This immune evasion is accomplished by using cell-surface-associated phthiocerol dimycoceroserate (PDIM) lipids to mask underlying pathogen-associated molecular patterns (PAMPs). In the absence of PDIM, these PAMPs signal a Toll-like receptor (TLR)-dependent recruitment of macrophages that produce microbicidal reactive nitrogen species. Concordantly, the related phenolic glycolipids (PGLs) promote the recruitment of permissive macrophages through a host chemokine receptor 2 (CCR2)-mediated pathway. Thus, we have identified coordinated roles for PDIM, known to be essential for mycobacterial virulence, and PGL, which (along with CCR2) is known to be associated with human tuberculosis. Our findings also suggest an explanation for the longstanding observation that M. tuberculosis initiates infection in the relatively sterile environment of the lower respiratory tract, rather than in the upper respiratory tract, where resident microflora and inhaled environmental microbes may continually recruit microbicidal macrophages through TLR-dependent signalling.
Subject(s)
Immune Evasion , Macrophages/microbiology , Membrane Lipids/metabolism , Mycobacterium/physiology , Animals , Female , Glycolipids/immunology , Glycolipids/metabolism , Lipids/biosynthesis , Lipids/immunology , Macrophages/cytology , Macrophages/immunology , Macrophages/metabolism , Mice , Mice, Inbred C57BL , Mycobacterium/pathogenicity , Mycobacterium tuberculosis/pathogenicity , Mycobacterium tuberculosis/physiology , Receptors, CCR2/metabolism , Toll-Like Receptors/immunology , Toll-Like Receptors/metabolism , Virulence/immunology , Zebrafish/microbiologySubject(s)
Glycolipids , Helminths , Hypersensitivity , Animals , Glycolipids/immunology , Helminths/immunology , Hypersensitivity/immunologyABSTRACT
The recognition of CD1-lipid complexes by T cells was discovered 20 years ago and has since been an emerging and expanding field of investigation. Unlike protein antigens, which are presented on MHC class I and II molecules, lipids can only be presented by CD1 molecules, a unique family of MHC-like proteins whose singularity is a hydrophobic antigen-binding groove. The processing and loading of lipid antigens inside this groove of CD1 molecules require localization to endosomal and lysosomal subcellular compartments and their acidic pHs. This particular environment provides the necessary glycolytic enzymes and lipases that process lipid and glycolipid antigens, as well as a set of lipid transfer proteins that load the final version of the antigen inside the groove of CD1. The overall sequence of events needed for efficient presentation of lipid antigens is now understood and presented in this review. However, a large number of important details have been elusive. This elusiveness is linked to the inherent technical difficulties of studying lipids and the lipid-protein interface in vitro and in vivo. Here, we will expose some of those limitations and describe new approaches to address them during the characterization of lipids and glycolipids antigen presentation.
Subject(s)
Antigens, CD1/metabolism , Antigens/immunology , Glycolipids/immunology , Immune System , Lipids/immunology , Animals , Antigen Presentation , Carrier Proteins/metabolism , Humans , T-Lymphocytes/immunologyABSTRACT
The glycoconjugates with BSA (bovine serum albumin) were synthesized using a next saccharide: disaccharide derivative M.leprae PGL-1 (phenolic glycolipid-1); a complex of the disaccharide fragment and the branched hexasaccharide fragment LAM (lipoarabinomannan); diarabinofuranose fragment LAM. These glycoconjugates were used as antigenic components for leprosy rapid serotest construction in immunochromatographic format (leprosy LF serotest). The data obtained with sera of leprosy patients, patients who have been in contact with leprosy, and healthy donors indicate that the most promising antigenic component is a BSA conjugate with two synthetic epitopes - a disaccharide derivative of PGL-1 and a branched hexasaccharide fragment of LAM. The leprosy LF serotest with such glycoconjugate demonstrated the greatest diagnostic sensitivity for main forms of leprosy - paucibacillary (PB) and multibacillary (MB).